Variation risks of SFRP2 hypermethylation between precancerous disease and colorectal cancer

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 10457-10465

  Sui, Chengguang ^a   Wang, Guang ^a   Chen, Qun ^b   Ma, Jianzhong ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal tumor; Hypermethylation; SFRP2 gene; Variation rule

Indexed keywords

MEMBRANE PROTEIN; SFRP2 PROTEIN, HUMAN;

ADENOMATOUS POLYP; COLORECTAL TUMOR; DNA METHYLATION; GENETICS; HUMAN; META ANALYSIS; PRECANCER; RISK FACTOR;

ADENOMATOUS POLYPS; COLORECTAL NEOPLASMS; DNA METHYLATION; HUMANS; MEMBRANE PROTEINS; PRECANCEROUS CONDITIONS; RISK FACTORS;

EID: 84922394857     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2313-2     Document Type: Article

References (23)

1. Ahn JB, Chung WB, Maeda O, Shin SJ, Kim HS, et al. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer. 2011;117:1847-54.
2. Kawano Y, Kypta R. Secreted antagonists of the Wnt signaling pathway. J Cell Sci. 2003;116:2627-34.
3. Kondo Y, Issa JP. Epigenetie changes in colorectal cancer. Cancer Metast Rev. 2004;23(1-2):29-39.
4. Dhir M, Montgomery EA, Glöckner SC, Schuebel KE, Hooker CM, Herman JG, et al. Epigenetic regulation of WNT signaling pathway genes in inflammatory bowel disease (IBD) associated neoplasia. Gastrointest Surg. 2008;12(10):1745-53.
5. Chen WD, Han ZJ, Skoletsky J, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst. 2005;97(15):1124-32.
6. Camp ER, Findlay VJ, Vaena SG, Walsh J, Lewin DN, Turner DP, et al. Slug expression enhances tumor formation in a noninvasive rectal cancer model. J Surg Res. 2011;170(1):56-63.
7. Nagasaka T, Tanaka N, Cullings HM, Sun DS, Sasamoto H, Uchida T, et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst. 2009;101(18):1244-58.
8. TakedaM, Nagasaka T, Dong-Sheng S, Nishie H, Oka T, Yamada E, et al. Expansion of CpG methylation in the SFRP2 promoter region during colorectal tumorigenesis. Acta Med Okayama. 2011;65(3): 169-77.
9. Pehlivan S, ArtacM, Sever T, Bozcuk H, Kilincarslan C, Pehlivan M. Gene methylation of SFRP2, P16, DAPK1, HIC1, and MGMT and KRAS mutations in sporadic colorectal cancer. Cancer Genet Cytogenet. 2010;201:128-32.
10. MüllerHM, Oberwalder M, FieglH,Morandell M, Goebel G, Zitt M, et al. Methylation changes in fecal DNA: a marker for colorectal cancer screening? Lancet. 2004;363(9417):1283-85.
11. Oberwalder M, Zitt M, Wöntner C, Fiegl H, Goebel G, Zitt M, et al. SFRP2 methylation in fecal DNA-a marker for colorectal polyps. Int J Colorectal Dis. 2008;23:15-9.
12. Chang E, Park DI, Kim YJ, Kim BK, Park JH, Kim HJ, et al. Detection of colorectal neoplasm using promoter methylation of ITGA4, SFRP2, and p16 in stool samples: a preliminary report in Korean patients. Hepatogastroenterology. 2010;57 (101):720-27.
13. Dao-rong W, Dong T. A study on relation of hypermethylation of secreted frizzled-related protein 2 (SFRP2) gene with colorectal cancer. Acta Univ Med Nanjing. 2007;27(11):1240-43.
14. QI Jian, Zhu You-qing, LI Xia, et al. Hypermethylation and expression of secreted frizzled-related proteins genes in different stages of colorectal tumor. Chin J Dig. 2007; 27 (4):251-54
15. Huang Z-H. Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J Gastroenterol. 2007;13(6):950-54.
16. TangD,WangD-r, LiH-b. Combination analysis of hypermethyIated SFRPl and SFRP2 gene in fecal as a novel epigenetic biomarker panel for colorectal cancer screening. Journal of Nanjing Medical University. 2008;22(2):96-101.
17. Tang D, Xue Y-j, Wen-jie F, Wang D-r. Study of the role of methylated SFRP2 gene in colorectal cancer screening. Chin J Curr Adv Gen Surg. 2009;12(5):378-82.
18. Tang D, Wang D-r, Hai-feng Y, Li Y-k. The expression of hypermethylated secreted frizzled-related protein 2 gene in colorectal cancer. Chin J Gen Surg. 2010;25(6):480-83.
19. Yu H-f, Wang G-r, Zhang Y, Jiang C, et al. SFRP2 gene promoter hypermethylation and its clinicopathologic significance in colorectal carcinoma. Int J Surg. 2011;39(8):526-29.
20. Wai. K Leung, Ka-Fai To, Ellen P.S. Man, MichaelW.Y. Chan, et al. Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am J Gastroenteol. 2007; 102:1070-76
21. Pack SC, Kim HR, Lim SW, Kim HY, Ko JY, Lee KS, et al. Usefulness of plasma epigenetic changes of five major genes involved in the pathogenesis of colorectal cancer. Int J Colorectal Dis. 2013;28(1):139-47.
22. Azuara D, Rodriguez-Moranta F, de Oca J, Sanjuan X, Guardiola J, Lobaton T, et al. Novel methylation panel for the early detection of neoplasia in high-risk ulcerative colitis and Crohn's colitis patients. Inflamm Bowel Dis. 2013;19(1):165-73.
23. Li YW, Kong FM, Zhou JP, Dong M. Aberrant promoter methylation of the vimentin gene may contribute to colorectal carcinogenesis: a meta-analysis. Tumour Biol. 2014. DOI 10.1007/s13277-014-1905-1